Anlotinib Completed Phase 2 Trials for Malignancies Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01878448A Phase II Study of Anlotinib in STS Patients